secwatch / observer
8-K filed June 27, 2023, 7:59 PM ET ticker GNPX CIK 0001595248
other material confidence high sentiment negative materiality 0.65

Genprex provides clinical updates: Acclaim-1 Phase 2 expansion approved, patient dosing delayed to Q3 2023

Genprex, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Genprex, Inc. shareholders approved Election of Class III Directors at the 2023-06-27 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-06-27
Exact text from the filing
The Class III director nominees, Jose Antonio Moreno Toscano and J. Rodney Varner, were elected to serve until the 2026 annual meeting of stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the Class III directors were as follows: Name Votes For Votes Withheld Broker Non-Votes Jose Antonio Moreno Toscano 4,856,975 3,471,721 18,051,580 J. Rodney Varner 6,899,410 1,429,286 18,051,580
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Genprex, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-27 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-06-27
Exact text from the filing
The proposal to ratify the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023 was approved by the stockholders based upon the following votes: Votes For Votes Against Abstention Broker Non-Votes 25,044,860 1,105,061 230,355 0
View on SEC.gov

Browse all shareholder votes →

Genprex, Inc. filing history →

Source: SEC EDGAR
accession 0001437749-23-018626
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.